C
Eli Lilly and Company
LLY
$795.35
$7.160.91%
C
Hold
10/25/2024Upgraded
Eli Lilly and Company (LLY) was upgraded to C+ from C on 10/25/2024 due to an increase in the total return index.
Eli Lilly and Company (LLY) was upgraded to C+ from C on 10/25/2024 due to an increase in the total return index.
C
Hold
10/9/2024Downgrade
Eli Lilly and Company (LLY) was downgraded to C from C+ on 10/9/2024 due to a decline in the total return index.
Eli Lilly and Company (LLY) was downgraded to C from C+ on 10/9/2024 due to a decline in the total return index.
C
Hold
9/4/2024Upgraded
Eli Lilly and Company (LLY) was upgraded to C+ from C on 9/4/2024 due to an increase in the total return index and volatility index.
Eli Lilly and Company (LLY) was upgraded to C+ from C on 9/4/2024 due to an increase in the total return index and volatility index.
C
Hold
8/20/2024Downgrade
Eli Lilly and Company (LLY) was downgraded to C from C+ on 8/20/2024 due to a noticeable decline in the total return index, solvency index and dividend index. The quick ratio declined from 0.67 to 0.6, and debt to equity increased from 2.06 to 2.14.
Eli Lilly and Company (LLY) was downgraded to C from C+ on 8/20/2024 due to a noticeable decline in the total return index, solvency index and dividend index. The quick ratio declined from 0.67 to 0.6, and debt to equity increased from 2.06 to 2.14.
C
Hold
8/5/2024Upgraded
Eli Lilly and Company (LLY) was upgraded to C+ from C on 8/5/2024 due to an increase in the total return index, valuation index and dividend index.
Eli Lilly and Company (LLY) was upgraded to C+ from C on 8/5/2024 due to an increase in the total return index, valuation index and dividend index.
C
Hold
7/18/2024Downgrade
Eli Lilly and Company (LLY) was downgraded to C from C+ on 7/18/2024 due to a noticeable decline in the growth index, total return index and volatility index. EBIT declined 14.33% from $3.19B to $2.74B, and total revenue declined 6.26% from $9.35B to $8.77B.
Eli Lilly and Company (LLY) was downgraded to C from C+ on 7/18/2024 due to a noticeable decline in the growth index, total return index and volatility index. EBIT declined 14.33% from $3.19B to $2.74B, and total revenue declined 6.26% from $9.35B to $8.77B.
C
Hold
3/28/2024Upgraded
Eli Lilly and Company (LLY) was upgraded to C+ from C on 3/28/2024 due to an increase in the total return index and volatility index.
Eli Lilly and Company (LLY) was upgraded to C+ from C on 3/28/2024 due to an increase in the total return index and volatility index.
C
Hold
3/13/2024Downgrade
Eli Lilly and Company (LLY) was downgraded to C from C+ on 3/13/2024 due to a large decline in the total return index, valuation index and dividend index.
Eli Lilly and Company (LLY) was downgraded to C from C+ on 3/13/2024 due to a large decline in the total return index, valuation index and dividend index.
C
Hold
2/22/2024Upgraded
Eli Lilly and Company (LLY) was upgraded to C+ from C on 2/22/2024 due to a significant increase in the growth index and volatility index. Earnings per share increased from -$0.0638 to $2.4188.
Eli Lilly and Company (LLY) was upgraded to C+ from C on 2/22/2024 due to a significant increase in the growth index and volatility index. Earnings per share increased from -$0.0638 to $2.4188.
C
Hold
11/3/2023Downgrade
Eli Lilly and Company (LLY) was downgraded to C from C+ on 11/3/2023 due to a major decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.95 to -$0.0638, the quick ratio declined from 0.63 to 0.58, and debt to equity increased from 1.71 to 1.81.
Eli Lilly and Company (LLY) was downgraded to C from C+ on 11/3/2023 due to a major decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.95 to -$0.0638, the quick ratio declined from 0.63 to 0.58, and debt to equity increased from 1.71 to 1.81.
C
Hold
8/25/2023Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 8/25/2023 due to a decline in the valuation index and dividend index.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 8/25/2023 due to a decline in the valuation index and dividend index.
B
Buy
8/10/2023Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 8/10/2023 due to a substantial increase in the total return index, volatility index and growth index. EBIT increased 36.37% from $1.71B to $2.34B, earnings per share increased from $1.49 to $1.95, and total revenue increased 19.43% from $6.96B to $8.31B.
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 8/10/2023 due to a substantial increase in the total return index, volatility index and growth index. EBIT increased 36.37% from $1.71B to $2.34B, earnings per share increased from $1.49 to $1.95, and total revenue increased 19.43% from $6.96B to $8.31B.
C
Hold
5/1/2023Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/1/2023 due to a substantial decline in the growth index, valuation index and volatility index. Earnings per share declined from $2.1404 to $1.49, EBIT declined 22.32% from $2.21B to $1.71B, and total revenue declined 4.68% from $7.3B to $6.96B.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/1/2023 due to a substantial decline in the growth index, valuation index and volatility index. Earnings per share declined from $2.1404 to $1.49, EBIT declined 22.32% from $2.21B to $1.71B, and total revenue declined 4.68% from $7.3B to $6.96B.
B
Buy
3/16/2023Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 3/16/2023 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 27.7% from $2.18B to $1.58B.
Eli Lilly and Company (LLY) was downgraded to B- from B on 3/16/2023 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 27.7% from $2.18B to $1.58B.
B
Buy
11/2/2022Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 11/2/2022 due to a significant increase in the growth index, solvency index and volatility index. Operating cash flow increased 166.21% from $820.7M to $2.18B, earnings per share increased from $1.05 to $1.61, and debt to equity declined from 1.98 to 1.59.
Eli Lilly and Company (LLY) was upgraded to B from B- on 11/2/2022 due to a significant increase in the growth index, solvency index and volatility index. Operating cash flow increased 166.21% from $820.7M to $2.18B, earnings per share increased from $1.05 to $1.61, and debt to equity declined from 1.98 to 1.59.
B
Buy
8/5/2022Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 8/5/2022 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 67.16% from $2.5B to $820.7M, earnings per share declined from $2.1 to $1.05, and EBIT declined 34.48% from $2.66B to $1.74B.
Eli Lilly and Company (LLY) was downgraded to B- from B on 8/5/2022 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 67.16% from $2.5B to $820.7M, earnings per share declined from $2.1 to $1.05, and EBIT declined 34.48% from $2.66B to $1.74B.
B
Buy
4/29/2022Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 4/29/2022 due to a noticeable decline in the growth index and total return index. Total revenue declined 2.37% from $8B to $7.81B.
Eli Lilly and Company (LLY) was downgraded to B from B+ on 4/29/2022 due to a noticeable decline in the growth index and total return index. Total revenue declined 2.37% from $8B to $7.81B.
B
Buy
4/18/2022Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 4/18/2022 due to an increase in the total return index.
Eli Lilly and Company (LLY) was upgraded to B+ from B on 4/18/2022 due to an increase in the total return index.
B
Buy
3/31/2022Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 3/31/2022 due to a decline in the valuation index, dividend index and volatility index.
Eli Lilly and Company (LLY) was downgraded to B from B+ on 3/31/2022 due to a decline in the valuation index, dividend index and volatility index.
B
Buy
3/15/2022Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 3/15/2022 due to a noticeable increase in the total return index, solvency index and growth index. Earnings per share increased from $1.22 to $1.8943, operating cash flow increased 32.2% from $1.63B to $2.16B, and total revenue increased 18.12% from $6.77B to $8B.
Eli Lilly and Company (LLY) was upgraded to B+ from B on 3/15/2022 due to a noticeable increase in the total return index, solvency index and growth index. Earnings per share increased from $1.22 to $1.8943, operating cash flow increased 32.2% from $1.63B to $2.16B, and total revenue increased 18.12% from $6.77B to $8B.
B
Buy
9/24/2021Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 9/24/2021 due to a decline in the total return index.
Eli Lilly and Company (LLY) was downgraded to B from B+ on 9/24/2021 due to a decline in the total return index.
B
Buy
9/9/2021Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 9/9/2021 due to a large increase in the growth index, total return index and volatility index. EBIT increased 10.51% from $1.74B to $1.92B, operating cash flow increased 4.6% from $1.7B to $1.78B, and earnings per share increased from $1.49 to $1.53.
Eli Lilly and Company (LLY) was upgraded to B+ from B on 9/9/2021 due to a large increase in the growth index, total return index and volatility index. EBIT increased 10.51% from $1.74B to $1.92B, operating cash flow increased 4.6% from $1.7B to $1.78B, and earnings per share increased from $1.49 to $1.53.
B
Buy
2/3/2021Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 2/3/2021 due to a substantial increase in the total return index, volatility index and growth index.
Eli Lilly and Company (LLY) was upgraded to B from B- on 2/3/2021 due to a substantial increase in the total return index, volatility index and growth index.
B
Buy
11/27/2020Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 11/27/2020 due to a substantial decline in the valuation index, growth index and dividend index. Operating cash flow declined 27.6% from $2.5B to $1.81B, and earnings per share declined from $1.55 to $1.33.
Eli Lilly and Company (LLY) was downgraded to B- from B on 11/27/2020 due to a substantial decline in the valuation index, growth index and dividend index. Operating cash flow declined 27.6% from $2.5B to $1.81B, and earnings per share declined from $1.55 to $1.33.
B
Buy
10/29/2019Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 10/29/2019 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 43.61% from $1.05B to $1.51B, and debt to equity declined from 5.73 to 4.56.
Eli Lilly and Company (LLY) was upgraded to B from B- on 10/29/2019 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 43.61% from $1.05B to $1.51B, and debt to equity declined from 5.73 to 4.56.
B
Buy
9/5/2019Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 9/5/2019 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $4.3103 to $1.44.
Eli Lilly and Company (LLY) was downgraded to B- from B on 9/5/2019 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $4.3103 to $1.44.
B
Buy
5/7/2019Upgraded
Eli Lilly and Company (LLY) was upgraded to B from C+ on 5/7/2019 due to a significant increase in the valuation index, growth index and efficiency index. Earnings per share increased from $1.1048 to $4.3103, and net income increased 277.03% from $1.13B to $4.24B.
Eli Lilly and Company (LLY) was upgraded to B from C+ on 5/7/2019 due to a significant increase in the valuation index, growth index and efficiency index. Earnings per share increased from $1.1048 to $4.3103, and net income increased 277.03% from $1.13B to $4.24B.
C
Hold
5/1/2019Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/1/2019 due to a decline in the total return index and volatility index.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/1/2019 due to a decline in the total return index and volatility index.
B
Buy
2/21/2019Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C on 2/21/2019 due to a substantial increase in the total return index, volatility index and valuation index.
Eli Lilly and Company (LLY) was upgraded to B- from C on 2/21/2019 due to a substantial increase in the total return index, volatility index and valuation index.
C
Hold
4/30/2018Upgraded
Eli Lilly and Company (LLY) was upgraded to C from C- on 4/30/2018 due to a noticeable increase in the growth index, solvency index and valuation index. Earnings per share increased from -$1.5764 to $1.16, debt to equity declined from 1.18 to 0.81, and EBIT increased 13.23% from $1.28B to $1.45B.
Eli Lilly and Company (LLY) was upgraded to C from C- on 4/30/2018 due to a noticeable increase in the growth index, solvency index and valuation index. Earnings per share increased from -$1.5764 to $1.16, debt to equity declined from 1.18 to 0.81, and EBIT increased 13.23% from $1.28B to $1.45B.
C
Hold
3/7/2018Downgrade
Eli Lilly and Company (LLY) was downgraded to C- from C on 3/7/2018 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.5274 to -$1.5764, net income declined 398.22% from $555.6M to -$1.66B, and total capital declined 10.9% from $28.49B to $25.39B.
Eli Lilly and Company (LLY) was downgraded to C- from C on 3/7/2018 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.5274 to -$1.5764, net income declined 398.22% from $555.6M to -$1.66B, and total capital declined 10.9% from $28.49B to $25.39B.
C
Hold
2/7/2018Downgrade
Eli Lilly and Company (LLY) was downgraded to C from C+ on 2/7/2018 due to a noticeable decline in the volatility index and total return index.
Eli Lilly and Company (LLY) was downgraded to C from C+ on 2/7/2018 due to a noticeable decline in the volatility index and total return index.
C
Hold
12/15/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 12/15/2017 due to a decline in the volatility index, valuation index and dividend index.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 12/15/2017 due to a decline in the volatility index, valuation index and dividend index.
B
Buy
11/30/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 11/30/2017 due to an increase in the volatility index, total return index and valuation index.
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 11/30/2017 due to an increase in the volatility index, total return index and valuation index.
C
Hold
10/27/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 10/27/2017 due to a substantial decline in the growth index, valuation index and total return index. Earnings per share declined from $0.95 to $0.5274, EBIT declined 7.41% from $1.31B to $1.22B, and total revenue declined 2.86% from $5.82B to $5.66B.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 10/27/2017 due to a substantial decline in the growth index, valuation index and total return index. Earnings per share declined from $0.95 to $0.5274, EBIT declined 7.41% from $1.31B to $1.22B, and total revenue declined 2.86% from $5.82B to $5.66B.
B
Buy
7/31/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/31/2017 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.1049 to $0.95, operating cash flow increased 385.76% from $339.9M to $1.65B, and the quick ratio increased from 0.78 to 0.92.
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/31/2017 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.1049 to $0.95, operating cash flow increased 385.76% from $339.9M to $1.65B, and the quick ratio increased from 0.78 to 0.92.
C
Hold
5/4/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B on 5/4/2017 due to a major decline in the growth index, valuation index and total return index. Earnings per share declined from $0.7271 to -$0.1049, operating cash flow declined 83.94% from $2.12B to $339.9M, and total revenue declined 9.24% from $5.76B to $5.23B.
Eli Lilly and Company (LLY) was downgraded to C+ from B on 5/4/2017 due to a major decline in the growth index, valuation index and total return index. Earnings per share declined from $0.7271 to -$0.1049, operating cash flow declined 83.94% from $2.12B to $339.9M, and total revenue declined 9.24% from $5.76B to $5.23B.
B
Buy
4/26/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 4/26/2017 due to an increase in the valuation index, total return index and dividend index.
Eli Lilly and Company (LLY) was upgraded to B from B- on 4/26/2017 due to an increase in the valuation index, total return index and dividend index.
B
Buy
4/11/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 4/11/2017 due to a decline in the volatility index, valuation index and dividend index.
Eli Lilly and Company (LLY) was downgraded to B- from B on 4/11/2017 due to a decline in the volatility index, valuation index and dividend index.
B
Buy
3/22/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 3/22/2017 due to a noticeable increase in the total return index, volatility index and valuation index.
Eli Lilly and Company (LLY) was upgraded to B from B- on 3/22/2017 due to a noticeable increase in the total return index, volatility index and valuation index.
B
Buy
7/29/2016Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/29/2016 due to a substantial increase in the growth index and efficiency index. Operating cash flow increased 528.82% from -$326.9M to $1.4B, earnings per share increased from $0.41 to $0.7069, and net income increased 69.89% from $440.1M to $747.7M.
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/29/2016 due to a substantial increase in the growth index and efficiency index. Operating cash flow increased 528.82% from -$326.9M to $1.4B, earnings per share increased from $0.41 to $0.7069, and net income increased 69.89% from $440.1M to $747.7M.
C
Hold
3/21/2016Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 3/21/2016 due to a noticeable decline in the volatility index, growth index and total return index. Earnings per share declined from $0.75 to $0.4492, EBIT declined 27.43% from $1.02B to $743.8M, and operating cash flow declined 27.19% from $1.1B to $804.3M.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 3/21/2016 due to a noticeable decline in the volatility index, growth index and total return index. Earnings per share declined from $0.75 to $0.4492, EBIT declined 27.43% from $1.02B to $743.8M, and operating cash flow declined 27.19% from $1.1B to $804.3M.
B
Buy
2/4/2016Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 2/4/2016 due to a decline in the volatility index.
Eli Lilly and Company (LLY) was downgraded to B- from B on 2/4/2016 due to a decline in the volatility index.
B
Buy
1/8/2016Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 1/8/2016 due to an increase in the valuation index.
Eli Lilly and Company (LLY) was upgraded to B from B- on 1/8/2016 due to an increase in the valuation index.
B
Buy
12/4/2015Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 12/4/2015 due to a noticeable decline in the total return index, valuation index and dividend index.
Eli Lilly and Company (LLY) was downgraded to B- from B on 12/4/2015 due to a noticeable decline in the total return index, valuation index and dividend index.
B
Buy
11/3/2015Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 11/3/2015 due to a noticeable increase in the valuation index, growth index and dividend index. Earnings per share increased from $0.56 to $0.75, operating cash flow increased 16.46% from $948.6M to $1.1B, and EBIT increased 0.11% from $1.02B to $1.02B.
Eli Lilly and Company (LLY) was upgraded to B from B- on 11/3/2015 due to a noticeable increase in the valuation index, growth index and dividend index. Earnings per share increased from $0.56 to $0.75, operating cash flow increased 16.46% from $948.6M to $1.1B, and EBIT increased 0.11% from $1.02B to $1.02B.
B
Buy
7/31/2015Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/31/2015 due to a substantial increase in the total return index, volatility index and growth index. Earnings per share increased from $0.4976 to $0.56, EBIT increased 7.46% from $952.7M to $1.02B, and total revenue increased 7.19% from $4.64B to $4.98B.
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/31/2015 due to a substantial increase in the total return index, volatility index and growth index. Earnings per share increased from $0.4976 to $0.56, EBIT increased 7.46% from $952.7M to $1.02B, and total revenue increased 7.19% from $4.64B to $4.98B.
C
Hold
5/21/2015Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/21/2015 due to a decline in the volatility index, total return index and valuation index.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/21/2015 due to a decline in the volatility index, total return index and valuation index.
B
Buy
4/13/2015Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 4/13/2015 due to an increase in the volatility index, valuation index and dividend index.
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 4/13/2015 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
3/27/2015Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 3/27/2015 due to a noticeable decline in the valuation index, total return index and solvency index. Debt to equity increased from 0.32 to 0.53, and the quick ratio declined from 1.11 to 0.77.
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 3/27/2015 due to a noticeable decline in the valuation index, total return index and solvency index. Debt to equity increased from 0.32 to 0.53, and the quick ratio declined from 1.11 to 0.77.
B
Buy
11/19/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 11/19/2014 due to a noticeable decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.68 to $0.468, EBIT declined 21.8% from $886.6M to $693.3M, and total revenue declined 1.22% from $4.94B to $4.88B.
Eli Lilly and Company (LLY) was downgraded to B- from B on 11/19/2014 due to a noticeable decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.68 to $0.468, EBIT declined 21.8% from $886.6M to $693.3M, and total revenue declined 1.22% from $4.94B to $4.88B.
B
Buy
10/24/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 10/24/2014 due to a decline in the total return index and volatility index.
Eli Lilly and Company (LLY) was downgraded to B from B+ on 10/24/2014 due to a decline in the total return index and volatility index.
B
Buy
10/9/2014Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 10/9/2014 due to an increase in the valuation index and dividend index.
Eli Lilly and Company (LLY) was upgraded to B+ from B on 10/9/2014 due to an increase in the valuation index and dividend index.
B
Buy
9/24/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 9/24/2014 due to a decline in the valuation index, solvency index and dividend index. The quick ratio declined from 1.35 to 1.2, and debt to equity increased from 0.29 to 0.3.
Eli Lilly and Company (LLY) was downgraded to B from B+ on 9/24/2014 due to a decline in the valuation index, solvency index and dividend index. The quick ratio declined from 1.35 to 1.2, and debt to equity increased from 0.29 to 0.3.
B
Buy
4/30/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B+ from A on 4/30/2014 due to a large decline in the growth index and valuation index. Operating cash flow declined 84.23% from $1.73B to $272.3M, total revenue declined 19.38% from $5.81B to $4.68B, and EBIT declined 12.8% from $993.3M to $866.2M.
Eli Lilly and Company (LLY) was downgraded to B+ from A on 4/30/2014 due to a large decline in the growth index and valuation index. Operating cash flow declined 84.23% from $1.73B to $272.3M, total revenue declined 19.38% from $5.81B to $4.68B, and EBIT declined 12.8% from $993.3M to $866.2M.
A
Buy
3/14/2014Upgraded
Eli Lilly and Company (LLY) was upgraded to A from A- on 3/14/2014 due to a noticeable increase in the volatility index and total return index.
Eli Lilly and Company (LLY) was upgraded to A from A- on 3/14/2014 due to a noticeable increase in the volatility index and total return index.
NYSE
11/29/2024 1:00PM Eastern
Quotes delayed
